Analysis of associations between high density lipoprotein structure and cholesterol efflux capacity in dyslipidemic patients treated with pitavastatin

Analysis of associations between high density lipoprotein structure and cholesterol efflux capacity in dyslipidemic patients treated with pitavastatin - High-Draw Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014352

Enrollment

Registered

2014-06-24

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who have LDL-C at least 140 mg/dL and fasting triglyceride <400 mg/dL, and does not receive treatment of anti-hyperlipidemic drugs (2)Patients who can provide a fasting blood sample (3)Patients over 20 years old (4)Patients who voluntarily provide informed consent with sufficient comprehension after receiving sufficient explanation of this study.

Exclusion criteria

Exclusion criteria: (1)Patients with contraindications to Livalo (2)Patients under treatment of anti-hyperlipidemic drugs (previous treatment of statin within 3 months, probucol within 6 months, or other anti-hyperlipidemic drugs within 1 month) (3)Previous treatments of hypertension excluding ARB, ACE inhibitor, and Ca blocker within 1 month (4)Patients with CK over upper limit of normal levels (5)Patients with AST and ALT over upper limit of normal levels (6)Smokers (7)Patients who cannot stop drugs prohibited for concomitant (8)Obese patients with BMI at least 30 kg/m2 (9)Patients with Nephrotic syndrome or diabetes mellitus (10)Patients with fasting plasma glucose at least 126 mg/dL or casual plasma glucose at least 200 mg/dL (11)Patients with 2 hours plasma glucose after 75g glucose load at least 200 mg/dL (12)Patients with HbA1c at least 6.5% (13)Patients with homozygous familial hypercholesterolemia (14)Patients under 20 years old (15)Patients judged to be inappropriate for this study by the investigators.

Design outcomes

Primary

Measure	Time frame
The association between cholesterol efflux capacity by HDL cholesterol and distribution of HDL subfractions and HDL proteins.	—

Countries

Japan

Contacts

Public ContactTakayuki Sawada

Chu-NET Office

chunet-office@umin.ac.jp0120-330-634

Outcome results